bioRxiv Science⌕ Search

Biology subjects

Rebel, H. G.

Publications and source records attributed to Rebel, H. G..

2 recordsLinked to original sources

A novel genetic strategy to interrogate an unknown phenotypic modifier: an Sdhc KO-Robertsonian mouse with a semi-homologous chromosome develops papillary thyroid carcinoma-like tumours

SDHD and SDHAF2 pathogenic variants confer a remarkable parent-of-origin tumour risk for the neuroendocrine tumours paraganglioma and pheochromocytoma. Paternally transmitted variants cause tumours but maternally transmitted variants do not. The Hensen hypothesis asserts that loss of an (unknown) imprinted gene(s), together the remaining wildtype SDH gene, is a prerequisite for tumour formation. This study had three objectives, first, as a test of the Hensen model, second, as a potential paraganglioma model, and finally, as a test of chromosomal configuration to interrogate large genomic regions carrying an unknown phenotypic modifier. We crossed an SDH gene knockout line to a Robertsonian (Rb) chromosome line harbouring the gene imprinting centre implicated in human tumourigenesis, to create a metacentric chromosome with characteristics of human chromosome 11. Distinct phenotypes were noted in various cohorts. In heterozygote Rb mice we noted both weight gain and frequent immune activation. In Sdhc knockout mice with both heterozygous and homozygous Rb chromosomes, thyroid abnormalities, including papillary thyroid carcinoma-like tumours, were common due to apparent synergy between the Sdhc KO and the Rb chromosome. We also found a single case of bilateral pheochromocytoma in which loss of Sdhc was not the driver. Although few studies of Robertsonian chromosomes in the mouse have addressed pathology or phenotype, this study suggests that chromosomal structure can dramatically impact clinical phenotype.

cancer biology↗

Behavioral-transcriptomic landscape of engineered T cells targeting human cancer organoids

Cellular immunotherapies are rapidly gaining clinical importance, yet predictive platforms for modeling their mode of action are lacking. Here, we developed a dynamic immuno-organoid 3D imaging-transcriptomics platform; BEHAV3D, to unravel the behavioral and underlying molecular mechanisms of solid tumor targeting. Applied to an emerging cancer metabolome-sensing immunotherapy: TEGs, we first demonstrate targeting of multiple breast cancer subtypes. Live-tracking of over 120,000 TEGs revealed a diverse behavioral landscape and identified a super engager cluster with serial killing capability. Inference of single-cell behavior with transcriptomics identified the gene signature of super engager killer TEGs, which contained 27 genes with no previously described T cell function. Furthermore, guided by a dynamic type 1 interferon (IFN-I) signaling module induced by high TEG-sensitive organoids, we show that IFN-I can prime resistant organoids for TEG-mediated killing. Thus, BEHAV3D characterizes behavioral-phenotypic heterogeneity of cellular immunotherapies and holds promise for improving solid tumor-targeting in a patient-specific manner.

cancer biology↗